The biotech week kicked off with a bang, not because of any macro factors like a new Federal Reserve program of monetary stimulus, or economic data emanating from Europe. However, two different biotechs had big moves today for company-specific reasons. Let's dive into these stories and highlight key investor takeaways.
Threshold Pharmaceuticals
Investors may worry that today's results could raise some red flags with the FDA if they play out in the larger phase 3 trial. However, if Threshold is correct that the control-arm patients skewed the results after switching to TH-302, then this may be a classic market overreaction. However, with plenty of competitors in the waiting in the wings, including Celgene's
Targacept
Investors are attracted to biotechs like Threshold and Targacept since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.